2020-06 | A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis | 유대현 |
2015-10 | Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product | 유대현 |
2014-12 | Analysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases | 유대현 |
2016-06 | Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis | 유대현 |
2020-12 | Autoantibodies against Protein Phosphatase Magnesium-Dependent 1A as a Biomarker for Predicting Radiographic Progression in Ankylosing Spondylitis Treated with Anti-Tumor Necrosis Factor Agents | 유대현 |
2015-10 | Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension | 유대현 |
2019-11 | Biologics for the treatment of adut-onset Still's disease | 유대현 |
2016-04 | Bone Scintigraphy in the Diagnosis of Rheumatoid Arthritis: Is There Additional Value of Bone Scintigraphy with Blood Pool Phase over Conventional Bone Scintigraphy? | 유대현 |
2017-06 | Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab | 유대현 |
2013-06 | CHARACTERISTICS, OUTCOMES, AND PREDICTORS OF COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN PATIENTS WITH RHEUMATOID ARTHRITIS | 유대현 |
2017-06 | Clinical characteristics and outcomes of diffuse alveolar hemorrhage in patients with systemic lupus erythematosus | 유대현 |
2013-12 | A Clinical Trial and Extension Study of Infliximab in Korean Patients with Active Rheumatoid Arthritis despite Methotrexate Treatment | 유대현 |
2016-01 | Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study | 유대현 |
2017-11 | Comparative effectiveness of the biosimilar CT-P13 | 유대현 |
2017-06 | Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis | 유대현 |
2018-08 | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial | 유대현 |
2014-07 | A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan | 유대현 |
2015-10 | Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study | 유대현 |
2017-07 | CT-P13 in the treatment of rheumatoid arthritis | 유대현 |
2019-08 | Deletion at 2q14.3 is associated with worse response to TNF-alpha blockers in patients with rheumatoid arthritis | 유대현 |